| Autor: |
O'Sullivan DE; Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada.; Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, AB T2N 1N4, Canada., Boyne DJ; Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada.; Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, AB T2N 1N4, Canada., Ford-Sahibzada C; Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, AB T2N 1N4, Canada., Inskip JA; Hoffmann-La Roche Limited, Mississauga, ON L5N 5M8, Canada., Smith CJ; Hoffmann-La Roche Limited, Mississauga, ON L5N 5M8, Canada., Sripada K; Hoffmann-La Roche Limited, Mississauga, ON L5N 5M8, Canada., Brenner DR; Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada.; Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, AB T2N 1N4, Canada., Cheung WY; Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada.; Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, AB T2N 1N4, Canada. |
| Abstrakt: |
The prognosis of early non-small-cell lung cancer (eNSCLC) remains poor. An understanding of current therapies and outcomes can provide insights into how novel therapies can be integrated into clinics. We conducted a large, retrospective, population-based cohort study of patients with de novo eNSCLC (stages IB, IIA, IIB, and IIIA) diagnosed in Alberta, Canada, between 2010 and 2019. The primary objectives were to describe treatment patterns and survival outcomes among patients with eNSCLC. A total of 5126 patients with eNSCLC were included. A total of 45.3% of patients were referred to a medical oncologist, ranging from 23.7% in stage IB to 58.3% in IIIA. A total of 23.6% of patients initiated systemic therapy (ST), ranging from 3.5% in stage IB to 38.5% in IIIA. For stage IIB and IIIA individuals who received surgery, adjuvant ST was associated with a decreased likelihood of death (hazard ratios (HR) of 0.77 (95% CI: 0.56-1.07) and 0.69 (95% CI: 0.54-0.89), respectively). In a Canadian real-world setting, stage IIB and IIIA patients who received adjuvant ST tended to have better survival than patients who did not, but future studies that provide adjustment of additional confounders are warranted. Examining referral pathways that account for disparities based on age, sex, and comorbidities in the real world would also provide further insights. |
